Background {#Sec1}
==========

Diabetes mellitus is characterized by hyperglycemia and carbohydrate metabolism, fat, and protein deficiency. It is one of the most common and costly chronic diseases in the world, and affects about 2--5% of adults in industrial societies \[[@CR1]\]. Given the increasing number of diabetes in the world, the World Health Organization (WHO) has described it as a hidden epidemic, with a global prevalence of 6.4% (285 million people) among 20--79 age group in 2010. However, this figure is projected to increase to 7.7% in 2030 (439 million per year), and to more than 600 million per year in 2035 \[[@CR2]\]. There are now more than 380 million people with diabetes worldwide, and this figure is estimated to be 29.1 million people in the United States, that is 9.3% of the total population \[[@CR3]\]. The statistics provided by the International Federation of Diabetes show that approximately 5 million people aged 20--79 years are suffering from diabetes in Iran, with a prevalence of 8.5% \[[@CR4]\]. Diabetes is known as one of the most important risk factors for cardiovascular disease, with diabetic patients being at risk of cardiovascular disease 2 to 4 times higher than the general population \[[@CR2]--[@CR4]\]. Diabetes can manifest as microvascular or macrovascular complications. The most important microvascular complications include nephropathy, retinopathy, neuropathy and the most important macrovascular complications include hypertension and coronary artery disease \[[@CR1]--[@CR4]\]. This chronic disease is also able to cause severe ocular, renal, and neuropathic complications in patients to blindness, renal, cardiovascular disease, amputation, and disability \[[@CR5]--[@CR7]\]. Such chronic and debilitating conditions have widespread effect on the ability of the individual and the daily activities of these patients, which in turn affects the quality of life in these patients \[[@CR8]\].

One of the long-term complications of diabetes is sexual dysfunction. Previous studies have shown the negative effects of this disease on the sexual function and health of people with diabetes in both genders \[[@CR9]--[@CR11]\]. Sexual health is defined by WHO as a physical, emotional, psychological, and social well-being in terms of sexual desire, not just lack of disease, dysfunction, or disability \[[@CR12]\], regardless of the range of sexual desires that are the basis of important behaviors and lead to sexual health. Sexual health is the result of interaction of cardiovascular, neurological, and hormonal factors and is influenced by individual factors, interpersonal relationships, traditions governing family and community, culture, and religion \[[@CR13], [@CR14]\]. Sexual dysfunction is a heterogeneous combination of disorders that is characterized as a major disorder in one's ability to respond to sexual response or sexual pleasure. These disorders include abnormalities in women's orgasm, arousal, pain, and unknown sexual dysfunction \[[@CR15]\]. Although various studies have reported high prevalence of sexual dysfunction in women with diabetes compared with non-diabetic women \[[@CR16]--[@CR31]\], the sexual problems of diabetic women and its related risk factors are not well defined and highlighted. There are also fewer studies on diabetic women than diabetic men \[[@CR32]--[@CR37]\]. In a study conducted in Iran, the prevalence of sexual dysfunction was reported to be 88% in women with type 2 diabetes \[[@CR22]\], which can significantly affect their interest, satisfaction, and ability to participate in sexual activity. Such conditions can be due to vascular, neurological, and psychological problems caused by diabetes or the result of negative effects of the drugs used in these patients \[[@CR32]--[@CR38]\]. On the one hand, the sexual health of diabetic patients, as a component of care, has often been neglected, perhaps because it has been considered by many individuals as a taboo and has thus been neglected \[[@CR39]\]. On the other hand, previous studies provide non-transparent and different information and various studies show in consistent scores for sexual dysfunction indices in women with type 2 diabetes. Thus, the aim of this systematic review and meta-analysis is to answer the questions, what is the level of overall prevalence of sexual dysfunction in women with type 2 diabetes and the overall score of female sexual function index in women with diabetes?

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

This study is a systematic review and meta-analysis and is the result of findings of previous relevant researches. First, articles published in domestic and foreign journals were retrieved by searching MEDLINE, Cochrane Library, Sciencedirect, Embase, Proquest databases and Persian databases, including Iranmedex, Magiran, and SID were restored during January 2000 to December 2018. The researcher carried out the searching process by using the keywords of Diabetes, Non-insulin dependent diabetes, Type 2 diabetes, Sexual dysfunction, and Women in Persian sources, and Diabetes, Non-insulin-dependent diabetes, Sexual dysfunction, women in English databases, as well as both Persian and English words in the Google scholar search engine. It should be noted that (AND) and (OR) operators were combined in order to provide more comprehensive access to all articles; therefore the OR operators was used to check the common names for a disorder like (Blood glucose OR Hyperglycemia), (Diabetes OR Non-insulin dependent diabetes), (Sexual Behavior OR Sexual Orientation), (Disorders OR Dysfunction). AND operator was also used between the keywords (Diabetes AND Non-Insulin-Dependent Diabetes AND Sexual Dysfunction) through the matching words in the MeSH browser.

Criteria for selection and evaluation of articles {#Sec4}
-------------------------------------------------

First, all the articles were collected using the selected keywords and when the search was completed, a list of abstracts was prepared and after hiding the articles' profile, including the name of the journal and the author, the full text of the articles was provided to the reviewers. Each article is read independently by two reviewers. If the article is rejected, the reason was mentioned. If there is a difference between two reviewers, the article was judged by the third reviewer and the third referee's opinion was taken into account. Inclusion criteria included Persian and English articles based on cross-sectional, case--control, and cohort studies to obtain the prevalence of sexual dysfunction in women with type 2 diabetes as well as to investigate the relationship between clinical and metabolic factors with sexual dysfunction in women with type 2 diabetes. Review, interventional articles, as well as articles with no access to their full text or poor rating quality, were excluded from the list of final articles. Moreover, studies that reported female sexual function indices (FSFI), including desire, arousal, lubrication, orgasm, satisfaction, and pain in women with type 2 diabetes were also separated from the final studies so that they will be used in the meta-analysis phase while investigating mean score and overall standard deviation of these indices. In order to investigate gray literature, that part of the evidence and documentation that has not been published for any reason, a comprehensive review on Google has been put on the agenda in the present study. To review the articles collected, a checklist of articles' profile, included the researcher's name, the article's title, the year and place of the study, the sample size, the prevalence of the disorder in studies based on the PRISMA chart, included a four-step process consisting of initial search and identification of the studies based on keywords, screening of articles based on duplicate searches and similar articles, the criteria for accepting articles based on inclusion and exclusion criteria, and finally the articles selected for entering meta-analysis, was prepared. Duplicate and multiple publications from the same population will be removed using citation management, software EndNote (version X7, for Windows, Thomson Reuters).

Quality assessment {#Sec5}
------------------

STROBE checklist was used to investigate the studies. This checklist consists of 22 sections, 18 of which are general and are used for all observational studies, including cohort, case--control, and cross-sectional. There are also 4 specific sections that depend on the type of study, and various methodological aspects that include objectives of the study, determining the appropriate sample size, type of study, sampling method, research population, data collection method, variables definition, and method, data collection tools, objectives under study, statistical test, and findings of the study. Accordingly, the maximum score is considered as 32, and articles with a score \> 14 were considered to be low in terms of quality assessment and excluded from the study.

Statistical analysis {#Sec6}
--------------------

Heterogeneity was investigated using the I^2^ test. Generally, heterogeneity is classified into three categories, heterogeneity \> 25% (low heterogeneity), 25--75% (average heterogeneity), and 75% \> higher (high heterogeneity). Data analysis was carried out using Comprehensive Meta-analysis software (Biostat, Englewood, NJ, USA version 3) and probability bias of the results was calculated by using funnel plot and Egger test (P \< 0.05), Begg and Mazumdar (P \< 0.1). Moreover, meta-regression test in two dimensions of sample size and years of research was used to investigate the effects of the potentially effective factors on the heterogeneity of the studies.

Results {#Sec7}
=======

Search output {#Sec8}
-------------

Based on studies on the prevalence of sexual dysfunction in women with type 2 diabetes, including articles published in domestic and foreign journals, and searching Iranmedex, Magiran, and SID databases (n = 89 articles), Medline (PubMed) (n = 112 articles), and Sciencedirect (n = 583 articles), Proquest (n = 63 articles), Embase, (n = 52 articles), Cochrane Library (n = 12 articles), and Google Scholar search engines(n = 366 articles), and a total of 1273 articles were obtained. Then, a total of 955 duplicate articles were excluded and 318 articles met the inclusion criteria based on preliminary studies. Finally, 25 articles were entered the meta-analysis phase after eliminating 285 unrelated articles and 8 articles with no access to their abstracts and original articles as well as their low quality during the secondary investigation (Fig. [1](#Fig1){ref-type="fig"}). Profiles of these articles were reported in Table [1](#Tab1){ref-type="table"} \[[@CR31], [@CR34], [@CR40]--[@CR62]\].Fig. 1The flowchart on the stages of including the studies in the systematic review and meta-analysis (PRISMA 2009) Table 1Specifications of studies entered the studyRowAuthor \[references\]Publication yearAreaParticipants' ageSample sizePrevalenceQuality assessment1Erol et al. \[[@CR40]\]2003Turkey38.8 ± 1.17251.3Moderate2Doruk et al. \[[@CR41]\]2005Turkey41 ± 1.15042Moderate3Najafi et al. \[[@CR42]\]2006Iran48.1 ± 9.52676Moderate4Mezones et al. \[[@CR43]\]2008Peru53.3 ± 4.13675Moderate5Ogbera et al. \[[@CR44]\]2009Nigeria50.5 ± 1.25887.9Moderate6Esposito et al. \[[@CR45]\]2010Italy57.9 ± 6.959553.4Moderate7Ziaeirad et al. \[[@CR46]\]2010Iran46.3 ± 5.29186.8High8Yencilk et al. \[[@CR34]\]2010Turkey39.2 ± 9.46280.6Moderate9Giugliano et al. \[[@CR47]\]2010Italy35--7065953.1Moderate10Nowosielski et al. \[[@CR48]\]2011Poland47.6 ± 7.0213327.06Moderate11Shi et al. \[[@CR49]\]2012China47.3 ± 7.110679.2High12Sharifiaghdas et al. \[[@CR50]\]2012Iran42.1 ± 5.94571Moderate13Cortelazzi et al. \[[@CR31]\]2013Italy18--503467.6Moderate14Erten et al. \[[@CR51]\]2013Turkey51.3 ± 5.83847.4Moderate15Vafaeimanesh et al. \[[@CR52]\]2014Iran48.2 ± 6.611053.6Moderate16Cordero et al. \[[@CR53]\]2014Mexico40--7012081.6Moderate17Shadman et al. \[[@CR54]\]2014Iran54.4 ± 9.842094.4Moderate18Bjerggaard te al \[[@CR55]\]2015Denmark65 ± 734868.3High19Elyasi et al. \[[@CR56]\]2015Iran42 ± 10.115078.7Moderate20Mazzilli et al. \[[@CR57]\]2015Italy36.6 ± 5.22417Moderate21Ammar et al. \[[@CR58]\]2016Tunisia40.8 ± 4.83050Moderate22Li et al. \[[@CR59]\]2016China51 ± 918475Moderate23Bak et al. \[[@CR60]\]2017Poland51.1 ± 9.711468Moderate24Turki et al. \[[@CR61]\]2017Saudi Arabia40--5027588.7Moderate25Marques et al. \[[@CR62]\]2018Portugal45--7011270.9Moderate

Heterogeneity and publication bias {#Sec9}
----------------------------------

The heterogeneity of the studies was evaluated using the I^2^ test and its value was obtained I^2^ = 94.5% indicating a high heterogeneity in the studies included. Therefore, the random effects model was used to combine the results of the studies. The results of the publication bias were measured using Egger test (Fig. [2](#Fig2){ref-type="fig"}), which was not statistically significant (P = 0.103), Begg and Manzumdar test also showed no significant publication bias in the present study (P = 0.833).Fig. 2Results of funnel plot on the prevalence of sexual dysfunction in women with type 2 diabetes

The total sample size was 3892 with the age range of 18--70 years. The overall prevalence of sexual dysfunction in women with type 2 diabetes was 68.6% based on the meta-analysis (95% CI 61.1--75.3%). The highest prevalence of sexual dysfunction was 94.4% among Iranian women with type 2 diabetes (95% CI 91.9%--96.3%) in 2014 \[[@CR58]\] and the lowest prevalence was observed among Italian women with type 2 diabetes 17% (95% CI 6.4--36.9%) in 2015 \[[@CR53]\] (Fig. [3](#Fig3){ref-type="fig"}). In this figure, the prevalence of sexual dysfunction is shown based on the random effects model where the black square indicates the prevalence rate and the length of the line segment on which is located shows the 95% CI interval in each study, the diamond sign also shows the prevalence rate in all studies.Fig. 3Overall prevalence of sexual dysfunction in women with type 2 diabetes based on the random model

Sensitivity analysis {#Sec10}
--------------------

A sensitivity analysis was performed to ensure the stability results, after removing each study results did not change (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Results of sensitivity analysis

Meta-regression analysis {#Sec11}
------------------------

In order to investigate the effects of potentially effective factors on the heterogeneity of the prevalence of sexual dysfunction in women with type 2 diabetes, meta-regression test was applied to two factors of sample size and year of study (Fig. [5](#Fig5){ref-type="fig"}). With an increase in the sample size, the overall prevalence of sexual dysfunction is reduced in women with Type 2 diabetes, which is statistically significant (Fig. [4](#Fig4){ref-type="fig"}) (P \< 0.05). It is also reported in this figure that with an increase in the year of the research, the overall prevalence of sexual dysfunction in women with type 2 diabetes is increased, which was also statistically significant (P \< 0.05).Fig. 5Meta-regression diagram of the prevalence of sexual dysfunction in women with type 2 diabetes by sample size and year of publication

Scores of female sexual function index {#Sec12}
--------------------------------------

In this study, information on FSFI score including desire, arousal, lubrication, orgasm, satisfaction, and pain were also extracted from the studies reviewed. The mean score in women of the case group (type II diabetes) was lower than that of the control group in all studies that examined these indices, and these values were statistically significant in all studies (Table [2](#Tab2){ref-type="table"}) (P \< 0.05).Table 2Specifications of studies entered the study (Female Sexual Function Index)Female Sexual Function IndexStudies \[references\]NCase (mean ± SD)NControl (mean ± SD)P valueDesireShi et al. \[[@CR49]\]1062.43 ± 0.991003.04 ± 1.040.000Nowosielski et al. \[[@CR48]\]1333.45 ± 1.241093.91 ± 1.130.000Mezones et al. \[[@CR43]\]362.6 ± 1.4363.8 ± 1.10.000Ogbera et al. \[[@CR44]\]582.3 ± 0.9383 ± 0.60.000Sharifiaghdas et al. \[[@CR50]\]4532 ± 1.19047 ± 56.50.000Afshari et al. \[[@CR75]\]1063.34 ± 1.371283.69 ± 1.190.000Ammar et al. \[[@CR58]\]302.86 ± 1.2304 ± 10.000Mazzilli et al. \[[@CR57]\]245.4 ± 1.2456.8 ± 1.70.000Bak et al. \[[@CR60]\]1016.8 ± 3.03898.9 ± 1.080.000Li et al. \[[@CR59]\]1842.38 ± 1.061462.82 ± 1.170.000ArousalShi et al. \[[@CR49]\]1062.54 ± 1.51003.26 ± 1.310.000Nowosielski et al. \[[@CR48]\]1333.75 ± 1.761094.4 ± 1.350.000Yencilk et al. \[[@CR34]\]623.09 ± 1.81505.47 ± 1.950.000Mezones et al. \[[@CR43]\]363.5 ± 1.9364.7 ± 0.80.000Veronelli et al. \[[@CR76]\]283.4 ± 0.39365 ± 0.160.000Ogbera et al. \[[@CR44]\]582 ± 1.5383.2 ± 1.50.000Sharifiaghdas et al. \[[@CR50]\]4538 ± 84.49061 ± 670.000Afshari et al. \[[@CR75]\]1063.66 ± 1.371283.79 ± 1.390.000Ammar et al. \[[@CR58]\]303.13 ± 0.7304.3 ± 0.80.000Cortelazzi et al. \[[@CR31]\]484.1 ± 0.16614.5 ± 0.110.000Naghavi et al. \[[@CR77]\]5022.8 ± 0.54015.2 ± 0.10.000Li et al. \[[@CR59]\]1842.47 ± 1.531463.07 ± 1.420.000LubricationShi et al. \[[@CR49]\]1063.25 ± 1.891004.22 ± 1.720.000Nowosielski et al. \[[@CR48]\]1334.53 ± 1.721095.01 ± 1.450.000Esposito et al. \[[@CR45]\]3222.5 ± 0.92733.4 ± 10.000Yencilk et al. \[[@CR34]\]624.31 ± 2.2505.68 ± 1.190.000Olarinoye et al. \[[@CR78]\]522.51 ± 2.07395 ± 1.910.000Erol et al. \[[@CR40]\]724.3 ± 1604.6 ± 0.60.000Mezones et al. \[[@CR43]\]363.2 ± 1.9364.5 ± 1.30.000Veronelli et al. \[[@CR76]\]283.6 ± 0.46365.6 ± 0.110.000Afshari et al. \[[@CR75]\]1063.62 ± 1.251284.05 ± 1.390.000Ammar et al. \[[@CR58]\]304.3 ± 0.6305.2 ± 0.50.000Cortelazzi et al. \[[@CR31]\]484.6 ± 0.17615 ± 0.120.000Naghavi et al. \[[@CR77]\]5022.4 ± 0.64015.2 ± 0.10.000Li et al. \[[@CR59]\]1843.14 ± 1.861463.88 ± 1.680.000OrgasmShi et al. \[[@CR49]\]1062.89 ± 1.761003.76 ± 1.660.000Nowosielski et al. \[[@CR48]\]1334.45 ± 1.231094.78 ± 1.210.000Yencilk et al. \[[@CR34]\]623.91 ± 2.7505.01 ± 1.960.000Olarinoye et al. \[[@CR78]\]522.02 ± 1.41393.22 ± 1.380.000Erol et al. \[[@CR40]\]723.5 ± 1604.5 ± 0.50.000Mezones et al. \[[@CR43]\]363.2 ± 1.8364.5 ± 1.10.000Veronelli et al. \[[@CR76]\]283.5 ± 0.45365.4 ± 0.120.000Afshari et al. \[[@CR75]\]1063.68 ± 1.421283.86 ± 1.470.000Ammar et al. \[[@CR58]\]304 ± 1.1305.17 ± 0.60.000Cortelazzi et al. \[[@CR31]\]484.5 ± 0.15615 ± 0.110.000Naghavi et al. \[[@CR77]\]5025.6 ± 0.34015.1 ± 0.10.000Bak et al. \[[@CR60]\]1016.8 ± 3.03898.9 ± 1.080.000Li et al. \[[@CR59]\]1842.78 ± 1.781463.48 ± 1.60.000SatisfactionShi et al. \[[@CR49]\]1063.63 ± 1.251004.27 ± 1.330.000Nowosielski et al. \[[@CR48]\]1334.59 ± 1.091094.94 ± 1.110.000Yencilk et al. \[[@CR34]\]624.51 ± 1.88505.34 ± 1.640.000Erol et al. \[[@CR40]\]723.4 ± 1604.3 ± 0.60.000Mezones et al. \[[@CR43]\]363.8 ± 1.3364.8 ± 0.90.000Ogbera et al. \[[@CR44]\]582.9 ± 2.2384 ± 1.90.000Afshari et al. \[[@CR75]\]1064.01 ± 1.331284.08 ± 1.360.000Ammar et al. \[[@CR58]\]304.13 ± 0.8305.25 ± 1.10.000Naghavi et al. \[[@CR77]\]5024.2 ± 0.24013.7 ± 0.10.000Bak et al. \[[@CR60]\]1018.1 ± 3.58912.8 ± 1.650.000PainYencilk et al. \[[@CR34]\]623.14 ± 1.92504.92 ± 2.010.000Olarinoye et al. \[[@CR78]\]522.43 ± 2.04395 ± 1.870.000Mezones et al. \[[@CR43]\]363.1 ± 1.7364.6 ± 1.30.000Veronelli et al. \[[@CR76]\]283.7 ± 0.49365.3 ± 0.240.000Sharifiaghdas et al. \[[@CR50]\]454 ± 8.99023 ± 25.30.000Li et al. \[[@CR59]\]1843.65 ± 1.941464.14 ± 1.770.000

Therefore, in order to equalize the values of each of the indices of sexual dysfunction in women with type 2 diabetes and their control group, the meta-analysis was used so as to evaluate the overall mean scores while reviewing all studies. Based on the results of meta-analysis (Figs. [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}, [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"} and [11](#Fig11){ref-type="fig"}), FSFIs scores (expressed as mean ± SD in *t* test analysis) in case and control groups were as follows: Desire, arousal, lubrication, satisfaction, orgasm, and pain in the case and control groups were respectively 3.4 ± 0.31 and 4.9 ± 0.7 (Fig. [6](#Fig6){ref-type="fig"}), 5.6 ± 2.1 and 7.3 ± 1.91 (Fig. [7](#Fig7){ref-type="fig"}), 5.9 ± 1.47 and 5.4 ± 5.1 (Fig. [8](#Fig8){ref-type="fig"}), 6.3 ± 4.2 and 6.3 ± 1.9 (Fig. [9](#Fig9){ref-type="fig"}), 5.4 ± 0.08 and 5.5 ± 1.5 (Fig. [10](#Fig10){ref-type="fig"}), 3.28 ± 0.19 and 5.1 ± 0.36 (Fig. [11](#Fig11){ref-type="fig"}). There was a significant difference between the case and control groups in all studies in terms of FSFI indices and the mean scores were lower in the case group (women with diabetes type 2) than the control group (P \< 0.05).Fig. 6Meta-analysis of mean score of desire index in case and control groups based on the random model Fig. 7Meta-analysis of the mean score of the arousal index in case and control groups based on the random model Fig. 8Meta-analysis of the mean score of the lubrication index in case and control groups based on the random model Fig. 9Meta-analysis of mean satisfaction score in case and control groups based on the random model Fig. 10Meta-analysis of the mean orgasm score in case and control groups based on the random model Fig. 11Meta-analysis of the mean pain score in case and control groups based on the random model

Discussion {#Sec13}
==========

Sexual dysfunction is defined as a person's inability to engage in the desired sexual intercourse. This disorder can be a symptom of problems with biological origin (biogenic) or intra-psychological or interpersonal conflicts (psychogenic) or a combination of these factors, and any type of stress, emotional disturbances, or lack of knowledge about physiology and sexual function can have a negative effect on the sexual function \[[@CR63]\]. Results of various studies revealed that 40% of couples suffer from sexual disorders or relative dissatisfaction with such disorders \[[@CR64]\]. Diabetic Individuals are also susceptible to various types of physical and mental disorders and one of the most important neglected care is sexual dysfunction in these patients \[[@CR65]\]. Sexual health is an important part of diabetes care, which is particularly neglected in women \[[@CR66], [@CR67]\]. Decreased nitric oxide production due to vascular dysfunctions decreases vascular vaginal relaxation and vascular, neurological, and psychiatric disorders are the main causes of reduced desire, vaginal discharge and lubrication, arousal, and orgasm in women with diabetes \[[@CR67]\]. Ovarian hormones have an effect on sexual desire; therefore, a factor such as diabetes can disrupt the secretion of these hormones and thus affects the sexual desire of women with diabetes \[[@CR66]\]. Diabetes also has a negative effect on the secretion of the endocrine glands at the beginning the vagina and may cause vaginal dryness and irritation, and the couples may experience a painful intercourse \[[@CR69]\]; however, another cause of painful intercourse include pelvic, virginal, uterine, and tube infections that may occur more frequently in women with diabetes are \[[@CR68], [@CR69]\]; therefore, diabetic women are more likely to experience decreased sexual desire, disrupted ovulation, early menopause, and even infertility than non-infected women \[[@CR64]--[@CR69]\] and these factors showed the importance of control and attention to women with type 2 diabetes.

Nappi et al. reported three critical physiologic requirements, including intact sex steroids, autonomic/somatic nerves, and arterial inflow/perfusion pressure to women's genital organs play fundamental roles in maintaining women's sexual function \[[@CR79]\] and Maseroli et al. reported Clitoral vascular resistance is positively associated with MetS, decreased sexual arousal, body image concerns, and increased somatized anxiety symptoms \[[@CR80]\].

Results of the present study and the review of 3892 individuals aged 18--70 years, the overall prevalence of sexual dysfunction in women with type 2 diabetes was 68.6% based on meta-analysis. Scores of all FSFI (sexual desire, arousal, vaginal lubrication, orgasms, satisfaction, and pain) in diabetic women were lower than non-diabetic women. In order to investigate the effects of potentially effective factors on the heterogeneity of the prevalence of sexual dysfunction in women with type 2 diabetes, meta-regression test was applied to two factors of sample size and year of study, With an increase in the sample size, the overall prevalence of sexual dysfunction is reduced in women with Type 2 diabetes, with an increase in the year of the research, the overall prevalence of sexual dysfunction in women with type 2 diabetes is increased, which was also statistically significant.

Results of a study in the United States reported that 43% of American women aged 18--59 years have sexual concerns \[[@CR68]\]; however, Dennerstein et al. \[[@CR69]\] reported that 42--88% of women suffer from sexual dysfunction during menstrual cycle. Pontiroli et al., in their systematic review and meta-analysis, reported that the chance for people with type 2 diabetes to develop sexual dysfunction is 2.4% more than that of non-affected people, whereas women with type 2 diabetes are 2 times more likely to have sexual dysfunction than non-affected women \[[@CR70]\]. Various studies reported higher prevalence for sexual dysfunction in the diabetic individuals in comparison with the general population, and this factor is considered as one of the most important factors affecting the marital satisfaction in people with sexual dysfunction \[[@CR71]\]. Meeking et al. \[[@CR72]\] reported a decrease in sexual desire, vaginal lubrication, satisfaction, and orgasm in 64%, 70%, 36%, and 47% of patients, respectively. In another study on patients with type 2 diabetes, Schriener-Engel et al. \[[@CR73]\] reported a decrease in sexual desire, vaginal lubrication, and orgasm in patients with type 2 diabetes; while other studies showed the negative impact of type 2 diabetes on sexual desire, sexual satisfaction, lubrication, and orgasm. Enzlin et al. \[[@CR74]\] also reports that 35% of women with Type 2 diabetes have orgasmic disorder. Results of this study indicate very high prevalence of sexual dysfunction in women with type 2 diabetes and it is necessary to pay attention to the correlation between sexual function and marital satisfaction. It is also very essential to pay attention to quality of life in women with diabetes so that health policy-makers, physicians, and healthcare providers to place this disorder among the most important and significant disorders in women with type 2 diabetes and to seek out a low prevalence of this disorder through psychological counseling and adopting treatment procedures so as to improve the quality of their marital life and prevent disorders and mental diseases in women.

Limitations {#Sec14}
===========

The most important limitation of the present study is the lack of access to the full text and low quality of some of the studies reviewed.

Conclusion {#Sec15}
==========

Regarding the high prevalence of sexual dysfunction in women with type 2 diabetes, it is essential for health policy-makers to take effective control as well as treatment measures, including periodic sexual care, for women with type 2 diabetes.
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:   World Health Organization

FSFI

:   Female Sexual Function Index

SID

:   Scientific Information Database

STROBE

:   Strengthening the Reporting of Observational Studies in Epidemiology for cross-sectional Study

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analysis
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